Latin America has become one of the top emerging regions for clinical trials due to its diverse and large patient population, as well as its highly qualified professionals for conducting clinical research.
The racial diversity in the region is a relevant factor to develop studies because the incidence of disease is higher in certain groups. With easy access to a diverse population, Latin America is one of the most ethnically multiple regions in the world.
This region has taken on a lead role in vaccine research due the number of Covid-19 trials conducted in the region since 2020. The region has gained recognition for rapid enrollment and high levels of adherence, whilst representing an opportunity for studies with a pediatric population, and ensuring compliance with quality standards.
The infrastructure for clinical trials has also grown more rapidly in Latin America than in other parts of the world. Large numbers of recruiting centers are opened every year; the number of Contract Research Organizations (CROs) located in the region has also significantly increased over the years.
Latin America has contributed with more than 100,000 patients in the development of 80 of the 233 vaccines prequalified by the WHO. There are 26 vaccine-preventable diseases of which 23 are covered by WHO prequalified vaccines. Latin America has participated in 21 of the 26 vaccines (the exceptions being: Tick Bite Encephalitis, Hepatitis E, Rabies, Typhoid Fever and Japanese Encephalitis).
VaxTRIALS provides turnkey vaccine clinical trial services, from selecting the most appropriate trial sites with a representative patient population, to choosing to work with the right partners, and then ensuring you are up to speed with local regulatory and clinical requirements.